WHO ICTRP trial
A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate…
NL-OMON54261 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON54261 |
|---|---|
| Public title | A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of rilvegostomig (AZD2936) Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01) |
| Scientific title | A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of rilvegostomig (AZD2936) Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01)… |
| Primary sponsor | Astra Zeneca |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Australia;Belgium;Brazil;China;Denmark;France;Japan;Netherlands;Spain;Taiwan (Province of China);United Kingdom;United States of America |
| Conditions | Lungcancer Non-small cell lungcarcinoma;10038666;Lungcancer;Non-small cell lungcarcinoma |
| Interventions | Following an initial screening period of up to 28 days, eligible participants will receive AZD2936 (rilvegostomig) every 3 weeks (Q3W) administered via intravenous (IV) infusion at the selected dose starting on Cycle 1 Day 1 for a maximum… |
| Registration date | Aug 23, 2023 |
| Target size | 18 |
| Secondary IDs | 2021-000857-23;NCT04995523;NL78207.056.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: